Indutrade AB (OTCPK:IDDWF)
$ 26.45 -2.03 (-7.13%) Market Cap: 9.28 Bil Enterprise Value: 10.28 Bil PE Ratio: 33.72 PB Ratio: 5.06 GF Score: 95/100

Q2 2026 Indutrade AB Earnings Call Transcript

Jul 16, 2026 / 07:30AM GMT
Release Date Price: $26.45

Key Points

Positve
  • Indutrade AB (IDTRY) reported a strong quarter with a 14% increase in total order growth, 8% of which was organic.
  • Net sales reached a record high of SEK9 billion, with a strong organic growth of 5%.
  • EBITDA margin improved to 14.7%, supported by good operational leverage and margin-accretive acquisitions.
  • The company successfully acquired nine companies in 2026, with a strong acquisition pipeline in place.
  • Cash flow from operating activities increased by 20%, and the order backlog is 8% higher than the same period last year.
Negative
  • Sales in Denmark were down due to lower deliveries to Novo Nordisk, impacting the overall performance in the Nordic region.
  • The Benelux region experienced a slightly negative development due to lower construction activity and tough comparisons.
  • Infrastructure & Construction segment was down 3%, still impacted by weaker general demand and lower order book values.
  • Technology & System Solutions had a lower EBITA margin compared to last year, affected by weak performance in a few project-oriented companies in the UK.
  • The financial net debt increased due to the increased acquisition pace, with net debt/EBITDA slightly higher than last year.
Operator

Welcome to the Indutrade Q2 presentation for 2026. (Operator Instructions) Now I will hand the conference over to CEO Bo Annvik; and CFO Patrik Johnson. Please go ahead.

Bo Annvik
Indutrade AB - President, Chief Executive Officer, Executive Director

Welcome and good morning on our behalf as well. We are glad to present a strong quarter, and let's start with the overall highlights.

We had a good development in many areas in the quarter, starting with the top-line development. Demand continued to improve and total order growth was 14%, of which 8% organically, with the majority of our companies growing. Continued positive book-to-bill of 105%, and the strongest demand was with companies having customers within the medtech and pharma area and also the energy sector.

Net sales increased 11% in total to record high SEK9 billion, with strong organic growth of 5%. EBITDA was also on a record high level, and EBITDA margin improved to 14.7%, with good operational leverage on the organic sales and margin accretive acquisitions. Cash flow from

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot